The minimum residual disease testing market involves molecular techniques for detecting the presence of tumor cells or tumor DNA in patients during or after cancer treatment. MRD testing leverages sensitive technologies such as next-generation sequencing, digital droplet PCR, and flow cytometry to screen residual blood, bone marrow, or cerebrospinal fluid for trace amounts of tumor biomarkers...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian